Find Locations
For hours, walk-ins and appointments.Synonyms
- T3, Total
Special Instructions
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Expected Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
Specimen Requirements
Specimen
Serum (preferred) or plasma
Volume
1 mL
Minimum Volume
0.7 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, or green-top (lithium heparin) tube. Do not use oxalate, EDTA, or citrate plasma.
Collection
If a red-top tube or plasma is used, transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Citrate plasma specimen; improper labeling
Test Details
Use
Thyroid function which is particularly useful in the diagnosis of T3 thyrotoxicosis, in which T3 is increased and T4 is within normal limits. T3 toxicosis is occasionally found in Graves' disease. It occurs with a single toxic nodule, multinodular thyrotoxicosis, and following treatment with T3 (Cytomel®).2 It is increased in and occasionally helpful for confirmation of diagnosis of conventional hyperthyroidism, in which commonly both T3 and T4 levels are increased. T3 is needed in patients with clinical evidence for hyperthyroidism, in whom the usual thyroid profile is normal or borderline.
Reported to be normal to slightly increased with familial dysalbuminemic hyperthyroxinemia.
Recommended for patients with supraventricular tachycardia, for patients with fatigue and weight loss not otherwise explained, or for those with proximal myopathy and in whom T4 levels are not elevated.3
Limitations
T3 is decreased with nonthyroidal chronic diseases and influenced by the state of nutrition. It is not helpful for evaluation of hypothyroidism. It may be normal with thyrotoxicosis (thyroxine thyrotoxicosis).4
Variations in TBG and other binding proteins can affect T3. Such increases may be found with use of oral contraceptives, pregnancy, and other binding protein abnormalities. Fasting causes T3 and TSH to decrease.5
Methodology
Electrochemiluminescence immunoassay (ECLIA)
Reference Interval
See table.1
Age | Range (ng/dL) |
|---|---|
0 to 3 d | 96−292 |
4 to 30 d | 62−243 |
31 d to 12 m | 81−281 |
13 m to 5 y | 83−252 |
6 to 10 y | 92−219 |
>10 y | 71−180 |
Additional Information
Increased T3 often occurs in hyperthyroidism, but in approximately 5% of cases only T3 is elevated, “T3 toxicosis.” Do not confuse T3 with T3 uptake; these are two different tests. The latter is done very commonly as part of the usual thyroid profile. Less than 1% of T3 is unbound.
Footnotes
1. Reference Intervals for Children and Adults.Elecsys Thyroid Test. Roche Diagnostics; May 2005.
2. Bethune JE. Interpretation of thyroid function tests. Dis Mon. 1989 Aug; 35(8):541-595. 2670494
3. Morley JE, Slag MF, Elson MK, Shafer RB. The interpretation of thyroid function tests in hospitalized patients. JAMA. 1983 May 6, 249(17):2377-2379. 6403725
4. Blank MS, Tucci JR. A case of thyroxine thyrotoxicosis. Arch Intern Med. 1987 May; 147(5):863-864. 3579439
5. Unger J. Fasting induces a decrease in serum thyroglobulin in normal subjects. J Clin Endocrinol Metab. 1988 Dec; 67(6):1309-1311. 3192683
References
Greenspan FS, Rapoport B. Thyroid gland. In: Greenspan FS, Forsham PH, eds. Basic and Clinical Endocrinology. Los Altos, Calif: Lange Medical Publications;1983:153.
Ingbar SH. Diseases of the thyroid. In: Braunwald E, Isselbacher KJ, Petersdorf RG, et al, eds. Harrison's Principles of Internal Medicine. 11th ed. New York, NY: McGraw-Hill; 1987:1732-1752.
Takamatsu J, Kuma K, Mozai T. Serum tri-iodothyronine to thyroxine ratio: A newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. J Clin Endocrinol Metab. 1986 May; 62(5):980-983. 3754263
Watts NB, Keffer JH. Practical Endocrine Diagnosis. 4th ed. Philadelphia, Pa: Lea & Febiger;1989.
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 002188 | Triiodothyronine (T3) | 3053-6 | 002188 | Triiodothyronine (T3) | ng/dL | 3053-6 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf